Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04959448 · ClinicalTrials.gov registry record
Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
A clinical trial of Chronic Rhinosinusitis With Nasal Polyposis, sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- 717
- Enrollment target
- 20
- Study locations
NCT04959448: Active study of Chronic Rhinosinusitis With Nasal Polyposis, sponsored by Regeneron Pharmaceuticals.
NCT04959448 is a study of Chronic Rhinosinusitis With Nasal Polyposis that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 717 participants. The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04959448, a study of Chronic Rhinosinusitis With Nasal Polyposis, is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 717 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objectives of the study are: * To longitudinally characterize the long-term effectiveness of DUPIXENT® through assessment of patient-reported symptoms, Health-Related Quality of Life (HRQoL) related to Chronic rhinosinusitis with nasal polyposis (CRSwNP) and other type 2 comorbidities, and their change over-time. * To characterize patients who receive DUPIXENT® for CRSwNP in a real-world setting with respect to their medical history, demographic and disease characteristics, and type 2 comorbidities The secondary objectives of the study are: * To characterize real-world utilization of DUPIXENT® for patients with CRSwNP * To collect patient and physician global assessment of disease severity and treatment satisfaction for patients receiving DUPIXENT® for CRSwNP * To collect long-term safety data for patients receiving DUPIXENT® for CRSwNP
Primary Outcome
Demographics includes but is not limited to gender, age, ethnicity, height, weight, BMI, education, current employment status, physician information.
Conditions Studied
Interventions
- DRUG DUPIXENT®
Study Locations (20)
California
- The Allergy and Rheumatology Medical Clinic - La Jolla
- ARK Clinical Research - Long Beach
- Scripps Health - Scripps Clinic Carmel Valley - San Diego
- Breathe Clear Institute - Torrance
- Allergy & Asthma Clinical Research - Walnut Creek
Florida
- AADRS Clincial Research Center - Coral Gables
- University of Florida - Gainesville
- Damask Physicians Group - Lake Mary
- University of South Florida - Tampa
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
- University of Illinois - Chicago
- The University of Chicago Medical Center UCMC Duchossois Center for Advanced Medicine DCAM - Chicago
- Asthma & Allergy Center of Chicago - Oak Park
Georgia
- Emory University Hospital Midtown - Atlanta
- IACT Health - Columbus
Alabama
- Excel ENT of Alabama - Birmingham
Arizona
- Medical Research of Arizona, a division of Allergy, Asthma & Immunology Associates - Scottsdale
Idaho
- Treasure Valley Medical Research - Boise
Indiana
- Indiana University Health - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 717 participants |
| Start Date | 2021-08-12 |
| Est. Completion | 2027-03-25 |
What the registry record for NCT04959448 still lists
NCT04959448 is an observational study that tracks outcomes without assigning an intervention. The registered 717 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Chronic Rhinosinusitis With Nasal Polyposis appearing as the primary indexed condition, and to 1 intervention - of which DUPIXENT® is the first listed.
NCT04959448 names 20 study sites across 9 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT04959448 about?
NCT04959448 is a clinical study titled "Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)". The primary objectives of the study are: * To longitudinally characterize the long-term effectiveness of DUPIXENT® through assessment of patient-reported symptoms, Health-Related Quality of Life (HRQoL) related to Chronic rhinosinusitis with nasal polyposis (CRSwNP) and other type 2 comorbidities, ...
What is the current status of trial NCT04959448?
This trial is currently active not recruiting. The enrollment target is 717 participants. The study started on 2021-08-12. Estimated completion is 2027-03-25.
What conditions does trial NCT04959448 study?
This clinical trial studies the following conditions: Chronic Rhinosinusitis With Nasal Polyposis.
What interventions are being tested in trial NCT04959448?
The interventions under investigation include: DUPIXENT® (DRUG).
Who is sponsoring clinical trial NCT04959448?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04959448 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04680000 · 716 participants · NA
Chronic Pain Management In Primary Care Using Behavioral Health Consultants
- NCT04916327 · 720 participants · NA
Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1
- NCT05047224 · 720 participants · NA
Addressing Disparities in Autism Spectrum Disorder Diagnosis Using a Direct-to-home Telemedicine Tool
- NCT05309395 · 720 participants · Phase 3
Food Prescriptions to Promote Affordable Diets
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI